Lexicon Pharmaceuticals (LXRX) Misses Q1 View By 3c

April 28, 2009 8:23 AM EDT

Lexicon Pharmaceuticals (Nasdaq: LXRX) reports Q1 LOSS of $0.16, 3 cents below the analyst estimate of ($0.13). Revenue for the quarter was $4.2 million, versus the consensus of $5.96 million.

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.


Related Categories

Earnings

Stocks Mentioned

LXRX 1.46

+0.00 +0.00%
Volume: 300,853
Track LXRX


Add Your Comment